(COMING SOON) Evotec Biologics, the biologics arm of Evotec SE, introduced its patented J. CHO™ high-expression system for antibody expression. J. CHO™ optimizes biotherapeutics production processes by delivering impressive productivity and quality for complex antibody formats. Designed in Chinese Hamster Ovary (CHO) mobiles, J. CHO achieves exceptionally high antibody titers, facilitating intensified and continuous manufacturing. Integrated into Evotec Biologics’ generation platform, J. CHO™ is helping to load manufactured goods (COGM) and streamline mobile devices. Line progression, which offers benefits such as improved manufacturability and time savings in the progression of candidate antibodies.
(PRESS RELEASE) HAMBURG, April 26, 2024 — /EuropaWire/ — Just – Evotec Biologics, the biologics segment of Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced the launch of its proprietary J. CHO™ High Formula (“J. CHO”) for antibody expression. As a component of Just: Evotec Biologics’ highly intensified continuous bioprocessing platform, J. CHO™ optimizes clinical and advertising biotherapeutics production processes by delivering higher productivity and highest quality of complex antibody formats, adding antibody candidates, Fc fusions, and bispecific antibodies.
Chinese hamster ovary mobiles (“CHO”) are a component of the biologics price chain and account for more than 70% of the production of recombinant healing proteins. Although CHO mobiles have impressive features in terms of protein expression, scalability, genetic engineering, and adaptability to environments, productivity varies widely among commercially available mobile lines.
J. CHO™ mobile lines are glutamine synthetase (“GS”) knockout mobile lines adapted to grow in Just-Evotec’s chemically explained infusion media, evolved for intensified and continuous manufacturing. J. CHO™ mobiles to achieve exceptionally superior antibody titers of more than four g/L/day in infusion, which is equivalent to approximately 30 g/L/day in fed batches. The main mobile host line chosen by J. CHO™ for its maximum expression and perfect functionality in mobile culture by infusion. Alternative J. CHO™ mobile lines are also available, which have been decided to supply a variety of glycans to meet the express needs of product quality.
Key Product Features
Dr. Linda Zuckerman, Global Executive Vice President of Biotherapeutics at Just – Evotec Biologics, commented: “The launch of J. CHO,™ our own high-throughput mobile line, is another step in our project to expand globally into biotherapeutics. As a component of Just’s technology platform, Evotec Biologics, J. CHO™ will help unlock the potential of biologics, delivering high levels of productivity and quality while optimizing clinical and advertising biotherapeutics production processes with a lower cost of products.
Integrated with Just’s proprietary generation platform, Evotec Biologics for biologics progression and highly intensified continuous bioprocessing, J. CHO™ helps to particularly reduce COGM. With J. CHO, ™ mobile line progression can be incorporated into J’s proprietary set. ™ MD Molecule Design, which enables the production of multiple variants of an antibody candidate with enhanced progression characteristics.
Benefits include:
To learn more about J. CHO,™ visit https://www. evotec. com/en/just-evotec-biologics/cell-line-development.
Media Contacts:
SOURCE: Evotec
MORE ABOUT EVOTEC, ETC. : Evotec appoints Aurélie Dalbiez as Director of Human Resources to drive organizational excellence. Breakpoint Therapeutics, backed by Evotec, names innovative cancer cure candidate BTX-011 for clinical development. Biotech Acceleration: Evotec and Claris Ventures team up to join forces to propel portfolio corporations forward.
EuropaWire (EW) is, in fact, the first pan-European press release and press release distribution service for Europe and the European Union, which aims to consolidate Europe’s global voice of news agencies and media. Submission forms, flexible PR pricing and budgets, granular targeting, unlimited maximum success across countries, markets, verticals, industries, audiences, languages, etc. , translation and localization for greater impact on local PR, in-depth distribution. . reports, metrics, and insights, adding measured PR success, reads, interactions, impact, etc. , with no limits on words, images, and multimedia to accompany your post, among other things. Your press releases will be among the press releases of Europe’s largest and most vital companies, brands and establishments.
HOW DO I GET STARTED?